Experts Matter. Find Yours.
Connect for media, speaking, professional opportunities & more.
UF researchers aim to improve nutrition for cancer patients
A new study and first-of-its-kind food pharmacy at UF aim to help patients with cancer access and eat nutritious foods, giving them the best possible shot at a healthy future. As many as a third of cancer patients face food challenges, particularly in rural areas. Good nutrition can improve outcomes during and after treatment. With a grant from the Florida Department of Health, a team of researchers at the University of Florida Health Cancer Center and Sylvester Comprehensive Cancer Center will first assess the community’s nutritional needs. Then they’ll test the usefulness of a food-focused digital tool designed to connect patients to helpful resources. An on-site food pharmacy will help patients not only get the food they need to thrive but also provide tools for lasting change. “We’re taking a community-based approach to holistic cancer care,” said Dejana Braithwaite, Ph.D., associate director for population sciences at the UF Health Cancer Center. “Patients consistently express that nutrition is an important issue for them during cancer treatment. We want to address nutritional needs from treatment through survivorship with a sustainable intervention. ASCENT brings science and community together to make that a reality in Florida.” Braithwaite, a professor and division chief in the UF Department of Surgery, is leading the multi-institution study with Tracy Crane, Ph.D., R.D.N., director of lifestyle medicine, prevention and digital health and co-lead of the Cancer Control Program at Sylvester, part of the University of Miami Health System. Researchers from the UF colleges of Journalism, Medicine, and Public Health and Health Professions and UF/IFAS Extension are participating. The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes study, which the researchers have nicknamed ASCENT, will focus on those affected by the most prevalent cancers in Florida, including breast, lung, colorectal, prostate and blood cancers. “Cancer survivors who follow a healthy dietary pattern have a lower risk of recurrence and death,” said Cora Best, Ph.D., R.D.N., an assistant professor of nutritional sciences in the UF College of Agricultural and Life Sciences and study team member. “Some cancer therapies have long-term or late side effects that increase the risk for chronic conditions, like osteoporosis, which can be alleviated with good nutrition. That means a healthy diet during and after oncologic treatment can enhance lifespan and quality of life.” Researchers will start by conducting interviews with patients, providers and community-based organizations. They want to understand how to best use resources to meet the nutritional needs of those with cancer, such as food security and diet quality. “Community outreach and engagement with various groups is a cornerstone of the study,” said Francis Dalisay, Ph.D., an associate professor in the UF College of Journalism and Communications who helped develop the interview guides. The team will use the information to build a diet intervention with online surveys and patient navigator support, which they will test in a randomized clinical study at UF Health and Sylvester. Patient navigators will connect patients with resources like community programs or specialist referrals. The food pharmacy, located at the UF Clinical and Translational Sciences Metabolic Kitchen, will help cancer patients get healthy, whole nutrient-dense foods like high-protein items, fruits, vegetables and pantry staples. It will also provide workshops, personalized recipes and meal plans. Although the United States is a wealthy nation, food insecurity remains common, including in Florida, Best said. “The ASCENT study pairs evidence-based dietary guidance for cancer survivors with innovative strategies to overcome barriers like food insecurity,” she said. Ultimately, the study aims to empower patients so they can address lifestyle factors in their control, boosting their well-being. “I am hopeful this study will provide patients with appropriate resources to improve their overall nutrition, especially those who are malnourished,” said Paul Crispen, M.D., the Cancer Center’s associate director for clinical research and a study adviser.
On March 10, 1876, Alexander Graham Bell spoke the first words ever transmitted over telephone: “Mr. Watson, come here; I want you.” This simple request to Bell’s assistant, Thomas Watson, marked a significant milestone in direct person-to-person communication. Now, 150 years later, this message has paved the way for advanced cellular technology in the form of satellites, wireless networks and the personal devices we carry everywhere. For Mojtaba Vaezi, PhD, associate professor of electrical and computer engineering at Villanova University and director of the Wireless Networking Laboratory, Bell’s few words spoken over telephone marked the beginning of an ongoing technological revolution. “One hundred fifty years ago when telephone communication first started, there was essentially a wired line and a transmitting voice,” said Dr. Vaezi. “That simple, basic transmission has transformed the field of communication technology in unimaginable ways.” According to Dr. Vaezi, five shifts have defined the past century and a half of communication technology: wired devices to wireless, analog to digital, voice to data, fixed landlines to mobile phones and human-to-human communication giving way to an increasing focus on machines and artificial intelligence. Early wireless networks were built around one device per person. Today's networks must support multiple devices per person, plus the technology behind innovations such as smart homes, driverless cars and even remote surgery. “Applications are much more diverse now, so communication has to follow,” said Dr. Vaezi. “A big portion of communication now, in terms of number of connections to the network, is from machine to machine—not human to human or even human to machine." The growing number of connections can cause a host of issues for users. When multiple users share the same wireless spectrum simultaneously, their signals interfere with one another—a problem that is becoming more acute as the number of connected devices increases exponentially. Dr. Vaezi’s research at Villanova focuses on developing techniques that allow multiple users to transmit messages on the same frequency at the same time and still be understood. Another vibrant research area of Dr. Vaezi’s involves Integrated Sensing and Communication (ISAC). This field of study focuses on integrating wireless communications and radar so they can function within the same spectrum. “Historically, radar and wireless communication work in different bandwidths or spectrums and use separate devices. Although they are related, they happen in different fields,” said Dr. Vaezi. “Almost every communication scheme that has been developed has focused on this: How can we better utilize the spectrum?” ISAC is increasingly important as new innovations like driverless cars become fixtures in everyday life. These vehicles rely on radar to continuously scan for hazards, and when a hazard is detected, a signal must be sent to trigger safety mechanisms. Currently, the radar and communications systems operate on separate bandwidths using separate hardware. Dr. Vaezi's research explores how both functions could be housed in a single device running on one shared spectrum. Areas of study like Dr. Vaezi’s that focus on machine to machine communication are becoming increasingly relevant as communication technology evolves and moves away from simple person to person messaging. As for the next big milestone in communications, Dr. Vaezi is looking ahead to the implementation of 6G by 2030, though he tempers expectations. For most users, the change will feel modest, amounting to slightly faster device speeds. The most massive shift with 6G will be the amount of added coverage in areas that previously did not have network accessibility. “Say you order a package and it’s coming from somewhere abroad,” explained Dr. Vaezi. “6G will add network coverage over oceans, so you’ll be able to track your package in real time using that satellite technology.” The sixth generation of cellular technology will continue to connect our world and optimize current communications to accommodate more users and devices that need network access each day. It is far different from Alexander Graham Bell’s historic phone call 150 years ago. That brief exchange over a single wired line laid the groundwork for a communications ecosystem that now supports billions of devices, complex data networks and emerging technologies yet to be seen. It also serves as a reminder that despite how far communication technology has come, and how complex it has gotten, it all shares a common, simple goal: to transmit information from one point to another.
Surgery past 65? Brain health screening can aid recovery
Before surgery, your doctor will order evaluations to identify any health problems that may need to be addressed before the procedure. This typically includes medical histories, laboratory tests and checking blood pressure, heart rate and temperature. There’s one vital sign that is often not on the list, but is crucial for older adults: screening for mental and cognitive health. “There is an overwhelming amount of evidence that presurgical brain health predicts complications after surgery,” said Catherine Price, Ph.D., a professor in the University of Florida College of Public Health and Health Professions Department of Clinical and Health Psychology and the UF College of Medicine Department of Anesthesiology. “For example, individuals with weaknesses in memory and attention and people with neurodegenerative diseases, such as Parkinson’s, have higher rates of confusion and memory complications that affect their recovery from surgery.” Research by Price and others has shown that a patient’s cognitive, memory and mental health status before surgery is an excellent indicator of whether they will experience cognitive problems such as delirium, a common complications in older adults after surgery. Delirium, characterized by confusion, disorientation and impaired awareness, can lead to longer recovery times, increased dementia risk, higher mortality rates and health care costs. Price founded and directs the University of Florida Perioperative Cognitive Anesthesia Network, or PeCAN, a first-of-its-kind, multidisciplinary program that seeks to identify older adults who may be at risk of developing cognitive problems after surgery so that clinicians can intervene. In recent findings published in the journal Anesthesia and Analgesia, Price and her colleagues report on two years of PeCAN patient data. Of the thousands of patients over age 65 who received presurgical screening, 23% were found to have issues with their cognitive performance, yet only 2% of the patients screened had a previous note in their medical charts indicating they had a cognitive impairment. “It’s so important to know when an individual has cognitive complications because that changes their care path,” Price said. “From medication to monitoring, the patient’s care is more complex for the perioperative team and family.” For PeCAN patients identified as being at risk for postsurgery cognitive problems, Price and her team will share tailored recommendations with the patient’s care team before, during and after surgery. These may include more monitoring during anesthesia and medication adjustments, such as using medications for nausea and pain management less likely to contribute to delirium. The PeCAN team also might offer the surgical care team specific communication strategies. For example, health care providers should repeat information several times for patients who have trouble remembering new material and ask them to write it down. Recently published research by Price and colleagues found PeCAN patients reported the focus on brain health improved confidence in their surgical team and care plan. Health care systems are only starting to incorporate preoperative brain health teams like PeCAN. Until they are offered more frequently, Price offers a few steps anyone can take to help protect brain health, including a focus on reducing inflammation in the body prior to surgery. To help achieve this: Optimize nutrition. Reduce your intake of added sugars and refined carbohydrates, like white bread. Get good sleep. Improve sleep hygiene so you are well-rested. “Sleep is essential for the brain for a number of reasons,” Price said. Reduce alcohol intake to limit inflammation and dehydration. Pay attention to your medications. Follow your care team’s instructions. Enlist a family member or caregiver to help you keep tabs on what you’re taking, how much and how often. Practice techniques to limit anxiety, such as visualization and deep breathing. The box breathing method is an easy one to remember: Breathe in slowly for four seconds. Hold your breath for four seconds. Slowly exhale for four seconds. Wait four seconds before inhaling again.
National Academy of Inventors welcomes five VCU College of Engineering researchers
The National Academy of Inventors (NAI) recently inducted five Virginia Commonwealth University (VCU) College of Engineering researchers as senior members. Chosen for their innovative engineering contributions, the honorees are recognized as visionary inventors whose groundbreaking research and patented technologies are driving meaningful societal and economic advancements across the national innovation landscape. “Invention represents the practical application of knowledge and stands as one of the many ways engineers can make a positive impact on their communities and the world,” said Azim Eskandarian, D.Sc, the Alice T. and William H. Goodwin Jr. Dean of the VCU College of Engineering. “This year’s honorees exemplify the interdisciplinary nature of our field, leveraging advanced concepts from mechanical, biomedical, chemical and pharmaceutical engineering to address today’s most pressing challenges. We are immensely proud that our dedicated researchers have earned recognition as members of the esteemed National Academy of Inventors.” The VCU College of Engineering NAI inductees are: Jayasimha Atulasimha, Ph.D. Engineering Foundation Professor Department of Mechanical & Nuclear Engineering An internationally recognized pioneer of straintronics, an approach to electrically control magnetism for ultra-low-energy computing, Atulasimha has made significant research contributions to next-generation memory, neuromorphic hardware and emerging quantum computing technologies. He holds four U.S. patents spanning energy-efficient magnetic memory, nanoscale computing architectures and medical tools. Atulasimha’s commercially viable inventions are funded by organizations like the Virginia Innovation Partnership Corporation and he leads multi-institutional collaborations that drive innovation in computing hardware, AI and quantum technologies with more than $10 million in funded research. Casey Grey, Ph.D. Postdoctoral Research Associate Department of Mechanical & Nuclear Engineering Bridging engineering and medicine, Grey’s work spans life‑saving stroke technologies, breakthrough respiratory and neurological care, and sustainable packaging. As a lead R&D scientist at WestRock, he helped create and commercialize the CanCollar® portfolio, a recyclable paperboard replacement for plastic beverage rings now used on five continents, eliminating thousands of tons of single‑use plastic annually. In medical device innovation, Grey’s patent and development work on a novel cyclic aspiration thrombectomy platform, currently in clinical trials, is advancing stroke treatment by enhancing clot removal efficiency and reducing long‑term disability. At the VCU College of engineering, Grey built a research and commercialization pipeline around neurological and respiratory technologies, securing eight provisional patents and leading multidisciplinary teams in neurology, neurosurgery, surgery, pharmacology and toxicology, internal medicine, and respiratory medicine. His work includes developing dry powder inhaler strategies for delivering life‑saving drugs to patients with acute respiratory distress syndrome (ARDS), a pediatric bubble CPAP system designed to protect brain development in premature infants, and non‑invasive, non‑pharmacological 40 Hz neuromodulation therapies to treat neurodegeneration and conditions with significant central nervous system complications, like sickle cell disease. In collaborations with the VCU Children’s Hospital and VCU Critical Care Hospital, Grey is leading two clinical studies that are translating these innovations to improve patient care. Ravi Hadimani, Ph.D. Associate Professor and Director of Biomagnetics Laboratory Department of Mechanical & Nuclear Engineering Hadimani founded RAM Phantoms LLC, a VCU startup company, commercializing anatomically accurate, MRI-derived brain phantoms for neuromodulation and neuroimaging applications. These brain phantoms help test and tune transcranial magnetic and deep brain stimulation technologies, improving clinical safety and enabling personalized therapy for patients. RAM Phantoms is also developing a highly-skilled workforce for employment in Virginia’s growing biomedical device industry. Beyond commercialization, Hadimani maintains a productive research program with more than $4.5 million in funding resulting in 125 original peer-reviewed publications, 17 current and pending patents, a book, and several book chapters. His biomagnetics lab serves as a training ground for undergraduate, graduate and Ph.D. students to hone their skills in innovation management, intellectual property strategy and startup development. Several students from Hadimani’s lab have engaged in translational research, patent co-authorship and start-up formation, cultivating a new generation of engineer-entrepreneurs equipped to drive future technological advances. Before joining VCU, Hadimani led the development of hybrid piezoelectric–photovoltaic materials that established FiberLec Inc., which commercialized multifunctional energy-harvesting fibers capable of converting solar, wind and vibrational energy into usable electricity. Worth Longest, Ph.D. Alice T. and William H. Goodwin, Jr. Distinguished Chair Department of Mechanical & Nuclear Engineering Uniting aerosol science, biomedical engineering and computational modeling, Longest is revolutionizing inhaled drug delivery. Working with collaborators, his lab has developed novel devices, formulations and delivery platforms that precisely target medications to the lungs, addressing conditions like cystic fibrosis, pneumonia, acute respiratory distress syndrome and neonatal respiratory distress syndrome. These innovations have resulted in multiple patents. Some of them have been licensed through commercial partnerships like Quench Medical, an organization advancing inhaled therapies for applications like lung cancer. Collaborating with the Gates Foundation and the lab of Michael Hindle, Ph.D., from the VCU Department of Pharmaceutics, Longest’s team developed a low-cost, high-efficacy aerosol surfactant therapy for pre-term infants based entirely on technology developed at VCU. The invention eliminates intubation, reduces dosage by a factor of 10, and cuts treatment costs. Over 9 million infant lives are projected to be saved by this technology between 2030 and 2050. Through a long-term collaboration with the U.S. Food and Drug Administration, Longest’s in vitro and computational methods provide federal regulatory guidance for generic inhaled medications. The VCU mouth-throat airway models developed under his leadership are used globally across the pharmaceutical industry and in government laboratories. Hong Zhao, Ph.D. Associate Professor Department of Mechanical & Nuclear Engineering Zhao holds 40 patents with innovations spanning additive manufacturing, stretchable electronics, inkjet printing technologies and superoleophobic materials that repel oils, greases, and low-surface-tension liquids. Her research has applications across health care, sustainable energy and advanced manufacturing. Prior to joining the College of Engineering, Zhao served as a senior research scientist and project leader at the Xerox Research Center, where she developed high-performance materials and printing technologies for commercial deployment. Her industry experience makes Zhao’s lab a hub for innovation and mentorship, with students engaging in innovative research and co-authoring publications. Zhao is an invited reviewer for more than 50 premier journals and grant agencies. “Working with distinguished researchers and innovators like those inducted into the National Academy of Inventors is a great honor for me,” said Arvind Agarwal, Ph.D., chair of the Department of Mechanical & Nuclear Engineering and NAI fellow. “They are an inspiration and showcase the kind of impact engineers can make. Having all five of these innovators as part of our department amplifies the scientific richness of our college and its societal impact. They advance the college’s mission of Engineering for Humanity, with research that brings a positive change to our world.” The 2026 NAI class of senior members, composed of 231 emerging inventors from NAI’s member institutions, is the largest to date. Hailing from 82 NAI member institutions across the globe, they hold over 2,000 U.S. patents.
Surprising finding could pave way for universal cancer vaccine
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to “wake up” the immune system against cancer. Published today in Nature Biomedical Engineering, the University of Florida study showed that like a one-two punch, pairing the test vaccine with common anticancer drugs called immune checkpoint inhibitors triggered a strong antitumor response in laboratory mice. A surprising element, researchers said, was that they achieved the promising results not by attacking a specific target protein expressed in the tumor, but by simply revving up the immune system — spurring it to respond as if fighting a virus. They did this by stimulating the expression of a protein called PD-L1 inside of tumors, making them more receptive to treatment. The research was supported by multiple federal agencies and foundations, including the National Institutes of Health. Senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research, said the results reveal a potential future treatment path — an alternative to surgery, radiation and chemotherapy — with broad implications for battling many types of treatment-resistant tumors. “This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus — so long as it is an mRNA vaccine — could lead to tumor-specific effects,” said Sayour, principal investigator at the RNA Engineering Laboratory within UF’s Preston A. Wells Jr. Center for Brain Tumor Therapy. “This finding is a proof of concept that these vaccines potentially could be commercialized as universal cancer vaccines to sensitize the immune system against a patient’s individual tumor,” said Sayour, a McKnight Brain Institute investigator and co-leader of a program in immuno-oncology and microbiome research. Until now, there have been two main ideas in cancer-vaccine development: To find a specific target expressed in many people with cancer, or to tailor a vaccine that is specific to targets expressed within a patient's own cancer. “This study suggests a third emerging paradigm,” said Duane Mitchell, M.D., Ph.D., a co-author of the paper. “What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients — even possibly leading us to an off-the-shelf cancer vaccine.” For more than eight years, Sayour has pioneered high-tech anticancer vaccines by combining lipid nanoparticles and mRNA. Short for messenger RNA, mRNA is found inside every cell — including tumor cells — and serves as a blueprint for protein production. This new study builds upon a breakthrough last year by Sayour’s lab: In a first-ever human clinical trial, an mRNA vaccine quickly reprogrammed the immune system to attack glioblastoma, an aggressive brain tumor with a dismal prognosis. Among the most impressive findings in the four-patient trial was how quickly the new method — which used a “specific” or personalized vaccine made using a patient’s own tumor cells — spurred a vigorous immune-system response to reject the tumor. In the latest study, Sayour’s research team adapted their technology to test a “generalized” mRNA vaccine — meaning it was not aimed at a specific virus or mutated cells of cancer but engineered simply to prompt a strong immune system response. The mRNA formulation was made similarly to the COVID-19 vaccines, rooted in similar technology, but wasn’t aimed directly at the well-known spike protein of COVID. In mouse models of melanoma, the team saw promising results in normally treatment-resistant tumors when combining the mRNA formulation with a common immunotherapy drug called a PD-1 inhibitor, a type of monoclonal antibody that attempts to “educate” the immune system that a tumor is foreign, said Sayour, a professor in UF’s Lillian S. Wells Department of Neurosurgery and the Department of Pediatrics in the UF College of Medicine. Taking the research a step further, in mouse models of skin, bone and brain cancers, the investigators found beneficial effects when testing a different mRNA formulation as a solo treatment. In some models, the tumors were eliminated entirely. Sayour and colleagues observed that using an mRNA vaccine to activate immune responses seemingly unrelated to cancer could prompt T cells that weren’t working before to actually multiply and kill the cancer if the response spurred by the vaccine is strong enough. Taken together, the study’s implications are striking, said Mitchell, who directs the UF Clinical and Translational Science Institute and co-directs UF’s Preston A. Wells Jr. Center for Brain Tumor Therapy. “It could potentially be a universal way of waking up a patient’s own immune response to cancer,” Mitchell said. “And that would be profound if generalizable to human studies.” The results, he said, show potential for a universal cancer vaccine that could activate the immune system and prime it to work in tandem with checkpoint inhibitor drugs to seize upon cancer — or in some cases, even work on its own to kill cancer. Now, the research team is working to improve current formulations and move to human clinical trials as rapidly as possible. While the experimental mRNA vaccine at this point is in early preclinical testing — in mice not humans — information about available nonrelated human clinical trials at UF Health can be viewed here.
Most patients taking popular weight loss and diabetes medications such as Ozempic and Wegovy can safely continue them before gynecologic surgery, according to a new journal article from ChristianaCare published in Obstetrics & Gynecology. The review found that serious anesthesia risks linked to these drugs are uncommon for most patients and can usually be managed through individualized planning rather than stopping the medication. The paper is the first to take a focused look at glucagon-like peptide-1 receptor agonists, commonly called GLP-1 drugs, in gynecologic surgery. These medications were first approved to treat diabetes and are now widely used to support weight loss and metabolic health, which refers to how the body processes sugar and energy. “Our study shows that the evidence does not support routinely stopping these medications before surgery and that the actual risk is low for most patients,” said Michelle Pacis, M.D., MPH, senior author of the study and a minimally invasive gynecologic surgeon at ChristianaCare. Why these medications raised concerns GLP-1 drugs work in part by slowing how quickly the stomach empties. This helps patients feel full longer, but it also raises concerns for surgery. Doctors worry that food remaining in the stomach could increase the risk of aspiration, when stomach contents enter the lungs during anesthesia. Because of this, early recommendations often advised stopping GLP-1 medications before surgery. The ChristianaCare review found that this approach was largely based on caution rather than strong evidence. The authors reviewed data from multiple studies, including large patient groups, that examined outcomes in people taking GLP-1 drugs during procedures. While some studies showed higher amounts of stomach contents, aspiration events were rare and occurred at rates similar to patients who were not taking the medications. New guidance reflects a change in thinking Recent national guidance from several medical societies now recommends a more tailored approach. Most patients can continue GLP-1 medications before surgery. For patients with higher risk factors, such as significant stomach symptoms or known delayed digestion, simple precautions can reduce risk. These precautions may include a clear liquid diet for 24 hours before surgery or closer monitoring during anesthesia. A clear liquid diet includes fluids like water, broth and clear juices. “This shift recognizes both the benefits of these medications and the importance of patient-specific decision making,” Pacis said. Why this matters for gynecologic surgery Many gynecologic surgeries require patients to be positioned in ways that can affect breathing and circulation. At the same time, many patients needing these procedures also have obesity or diabetes, which can increase surgical risk. GLP-1 medications can improve blood sugar control and support weight loss, helping patients enter surgery in better overall health and enhance recovery. Stopping these drugs without a clear reason may work against those benefits. Practical steps to support patient safety The study outlines several strategies care teams can use when patients remain on GLP-1 medications. These include thoughtful anesthesia planning, careful monitoring of heart and lung function, and, in select cases, the use of ultrasound to check stomach contents before surgery. “The goal is not to ignore risk, but to manage it wisely,” Pacis said. “For many patients, continuing these medications supports safer surgery and better recovery.” The authors note that more research is needed, particularly studies focused specifically on gynecologic surgery. Still, the findings offer clarity for patients and clinicians navigating a rapidly changing area of care. “This review helps bring evidence and balance to an issue that has caused a lot of confusion,” Pacis said. “It supports keeping patients on therapies that benefit their health whenever it is safe to do so.”
How ACL injury derailed Lindsey Vonn's heroic return to Olympic competition
An ACL rupture couldn't keep skiier Lindsey Vonn off the slopes to start this week's Olympics. But according to the University of Delaware's Dr. Karin Silbernagel, the injury likely contributed to her inability to land safely Sunday on the downhill course in Cortina d’Ampezzo, Italy. The crash ended her heroic return to competition Dr. Silbernagel, a professor of physical therapy, studies tendon injuries in the ankle and knee in elite athletes, especially Achilles ruptures and ankle function. She was quoted in an ESPN story about the rash of such injuries in the NBA and can specifically address the impact they could have on competition now and for the rest of an athlete's career. Her research shows that even after successful surgery, many athletes return to competition but not many among them return to peak explosiveness or durability. The impact a major injury would have on a fresh injury like Vonn's is obvious, she said. Dr. Silbernagel's research on ankle and knee injuries dates back to the early 2000s. She consults with professional sports teams relating to tendon injuries and is a consultant to the NFL's Musculoskeletal Committee. To connect directly with Dr. Silbernagel and arrange an interview, visit her profile and click the "contact" button. Interested members of the media can also send an email to MediaRelatons@udel.edu.
Gene Editing Breakthrough Offers New Hope for Head and Neck Cancer Patients
Researchers at the ChristianaCare Gene Editing Institute have made an important advance in treating head and neck cancers. By using CRISPR gene editing, the team found a way to restore how well chemotherapy works in tumors that have stopped responding to treatment. Their results, now published in Molecular Therapy Oncology, could change how doctors treat these aggressive cancers and give new hope to many patients who face limited options. Head and neck cancer is the seventh most common cancer worldwide, and cases are expected to rise by 30 percent every year by 2030. Even with progress in surgery, chemotherapy and immunotherapy, many patients still reach a point where treatment no longer works. The ChristianaCare team aimed to solve this challenge at its source. Targeting the Heart of Drug Resistance The researchers focused on a gene called NRF2. This gene acts like a master switch that helps cancer cells survive stress and resist chemotherapy. Because NRF2 plays such a central role in tumor growth, the team chose to develop a genetic therapy that disables the gene itself rather than targeting a single protein, which is common in traditional drug development. Since NRF2 is a transcription factor, shutting it down in a lasting way is more likely to succeed through CRISPR gene editing. Their major advance was showing that CRISPR can successfully disrupt NRF2 in head and neck cancer cells and in esophageal cancer cells. This work builds on earlier studies in lung cancer, where blocking NRF2 made tumors more sensitive to chemotherapy and improved survival in animal models. “Our goal was to break through the wall of drug resistance that so many patients face,” said Natalia Rivera Torres, Ph.D., the study’s lead author. “By precisely editing the NRF2 gene, we can make cancer cells vulnerable again to standard treatments. This could improve outcomes and quality of life.” Precision Matters: The Power of Target Choice The study also showed that the location of the CRISPR cut within the NRF2 gene makes a big difference. The strongest results came from targeting exon 4, a part of the gene that controls a key section of the NRF2 protein. Editing this region reduced NRF2 levels by 90 percent and made cancer cells much more sensitive to chemotherapy. In comparison, editing exon 2 was less effective even though it still caused high levels of gene disruption. The team also found that a process called exon skipping, where sections of genetic code are rearranged, can affect the outcome of gene editing. This discovery highlights how important careful design and testing are when building gene editing therapies. A Platform for Broader Impact ChristianaCare researchers saw the same results in both head and neck cancer cells and esophageal cancer cells. This suggests the strategy could help treat many solid tumors that have high levels of NRF2 and are known for strong drug resistance. “This is more than just a single experiment,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and senior author of the study. “We are building a platform that can be adapted to different cancers. Our earlier work in lung cancer showed the promise of this approach, and now we see it working in other hard to treat tumors. It is an exciting step toward making gene editing a meaningful part of cancer treatment.” Looking Ahead: Toward Clinical Application With these strong results, the team is now focused on finding the safest and most effective way to deliver the gene editing tools directly to tumors. Their goal is to reduce how much standard treatment a patient needs in order to get the best result with fewer side effects. “Drug resistance is one of the biggest challenges in cancer care,” Rivera Torres said. “If we can overcome it with gene editing, we could give patients more time, better quality of life and a renewed sense of hope.” Kmiec added, “We are committed to moving this technology forward quickly while always keeping the patient in mind. The future of cancer treatment is personal, precise and, we believe, within reach.”
Anuradha Godavarty, Ph.D., has joined the Virginia Commonwealth University (VCU) College of Engineering, bringing more than two decades of research leadership in optical imaging, medical device innovation and interdisciplinary training to the Department of Biomedical Engineering. “We are thrilled to welcome Dr. Godavarty to our department,” said Rebecca Heise, Ph.D., Inez Caudill, Jr. Distinguished Professor and chair of the Department of Biomedical Engineering. “She is an outstanding scholar and teacher who will expand our collaborations with VCU Health in many applications of optical imaging. Our students and faculty alike will benefit from her experience and mentorship.” Godavarty comes to VCU from Florida International University (FIU), where she served as director of the Optical Imaging Laboratory at FIU. Her work centered on designing and translating near‑infrared optical imaging technologies for clinical use, with applications ranging from breast cancer detection to functional brain mapping to wound assessment. Godavarty has a national reputation for developing portable, low‑cost imaging systems that improve access to care, including hand-held and smartphone-based near‑infrared imaging devices. Her research portfolio includes funding from the National Institutes of Health (NIH), National Science Foundation, Florida Department of Health and American Cancer Society, among others. Godavarty is also a fellow of the American Institute for Medical and Biological Engineering, a senior member of the International Society of Optics and Photonics and the National Academy of Inventors At VCU, Godavarty will expand her research program in optical imaging technologies while collaborating with clinicians, engineers and industry partners across the university and region. Her long‑term goals include advancing bedside imaging tools for wound care, cardiovascular applications and plastic surgery; strengthening global research partnerships; and training the next generation of optical imaging experts. “Virginia Commonwealth University’s engineering and health sciences ecosystem is an ideal place to grow translational research,” Godavarty said. “I look forward to building new collaborations, developing technologies that can make a meaningful difference in patient care and translating these innovations for real-world use by medical professionals.” Godavarty has played a major role in undergraduate education, serving as the undergraduate program director for biomedical engineering at FIU from 2016 to 2022 and leading the department through a successful Accreditation Board for Engineering and Technology (ABET) cycle. She organized FIU’s Annual Diabetes Awareness Day for four consecutive years and regularly engaged K‑12 students through hands-on demonstrations. Throughout her career, Godavarty has been deeply committed to mentoring. In addition to supervising doctoral, master’s and undergraduate students at FIU, she also advised high school students through outreach initiatives and supported several postdoctoral researchers. Her students have earned multiple awards, including NIH and Department of Defense fellowships, national postdoctoral awards and multiple university‑level honors.
The year was 2003, and John Speich, Ph.D., professor in the Department of Mechanical & Nuclear Engineering, felt like he had a clear sense of the direction his burgeoning career was heading in. Speich had recently completed his doctorate in mechanical engineering from Vanderbilt University, where he concentrated on robotics. Following Vanderbilt, Speich went on to become an associate professor at the Virginia Commonwealth University (VCU) College of Engineering, working with students in the Department of Mechanical & Nuclear Engineering. Leveraging his robotics expertise, Speich planned to continue his work developing robotics for medical surgery and rehabilitation. Then Speich got a call from Paul Ratz, Ph.D., a professor at the VCU School of Medicine, asking for assistance that would change the entire focus of Speich’s career. Ratz used a small robotic lever that moved up and down just a few millimeters to stretch tiny strips of bladder muscle and rings of artery, trying to determine how different chemical compounds changed the mechanical properties of the muscle. Speich was intrigued—this was a form of mechanical engineering. “In mechanical engineering, we pull on things to determine the mechanical properties,” says Speich. “Here, Dr. Ratz was pulling on pieces of bladder instead of the typical substances mechanical engineers are known to work with, like steel, aluminum or plastic.” Speich and Ratz began working together in 2003, and now, because of that unique partnership, nearly all of the research Speich does is about the bladder. “Before I started working with Dr. Ratz, I had never even heard the words neurourology or urodynamics,” says Speich. “Now, Neurourology and Urodynamics is the name of the journal I publish in the most.” Today, Speich collaborates on bladder biomechanics with two doctors at VCU Health. Adam Klausner, MD is a urologist and the interim chair of the new Department of Urology at VCU. Linda Burkett, MD is a urogynecologist from the Department of Obstetrics and Gynecology; prior to medical school, Burkett completed her bachelor’s degree in Biomedical Engineering from the VCU College of Engineering. Together, Speich, Klausner and Burkett aim to find non-invasive methods to characterize and diagnose overactive bladder, with the goal of allowing doctors to precisely match patients with the most effective treatments. A number of students across the VCU College of Engineering and VCU School of Medicine have aided in their research, including recent Biomedical Engineering graduate Mariam William. Speich’s primary methods of research involve Near-Infrared Spectroscopy (NIRS)—a non-invasive technology that uses light to measure tissue oxygenation and brain activity—and ultrasound imaging. By using NIRS to study the brain activity associated with the sudden urge to urinate, Speich and his team are working to pinpoint the brain’s role and determine whether it or the bladder is the primary cause of an individual’s condition. “There are a lot of potential causes of overactive bladder,” says Speich. “Some people may have more than one cause. Individual responses to these treatments vary; what works well for one patient may not work at all for the next. We want to give doctors better tools for quantifying information about their patients so they can make better decisions and more optimized treatments.” Thanks to research grants, including a National Institutes of Health (NIH) grant from 2015-2025, Speich has been able to make a number of important findings in his bladder research. His team has closely examined the bladder’s dynamic elasticity, investigating the biomechanical mechanisms that allow the bladder muscle to fill and expand. Another recent focus asks, “Bladder or Brain. Which is it?” Speich and his team developed a tool called a sensation meter that they use to help determine what an individual is feeling as their bladder is filling over time. All this groundbreaking research and medical school collaboration, and to think—Speich nearly missed the opportunity to enter this field entirely. “When I tell students about how I came to be involved in bladder biomechanics, I tell them, you will always keep learning throughout your entire career,” says Speich. “You never know where you’re going to end up. If you’re an engineer, you’re a problem solver, and there are all kinds of problems in areas like business and medicine—beyond the traditional areas people think of when they think of mechanical engineering.”
